Novavax (NVAX) Liabilities and Shareholders Equity (2016 - 2025)
Novavax (NVAX) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $1.2 billion in Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity fell 24.6% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $5.0 billion, down 22.64%, while the annual FY2025 figure was $1.2 billion, 24.6% down from the prior year.
- Liabilities and Shareholders Equity reached $1.2 billion in Q4 2025 per NVAX's latest filing, roughly flat from $1.2 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $2.8 billion in Q1 2022 and bottomed at $1.2 billion in Q4 2025.
- Average Liabilities and Shareholders Equity over 5 years is $1.9 billion, with a median of $1.8 billion recorded in 2023.
- Peak YoY movement for Liabilities and Shareholders Equity: soared 695.07% in 2021, then plummeted 45.58% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.6 billion in 2021, then decreased by 12.34% to $2.3 billion in 2022, then decreased by 20.42% to $1.8 billion in 2023, then fell by 13.19% to $1.6 billion in 2024, then fell by 24.6% to $1.2 billion in 2025.
- Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.2 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.3 billion in Q2 2025.